Calithera Biosciences company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

calithera.com

Stage

IPO | IPO

Total Raised

$101.24M

Date of IPO

10/2/2014

Market Cap

0.02B

Stock Price

0.20

About Calithera Biosciences

Calithera Biosciences, formerly Protein Activation Therapeutics, develops therapeutic approaches to the treatment of cancer by using small molecules to activate, rather than inhibit, enzymes. The company's first program is focused on developing activators of caspases, the proteases that induce apoptosis, for the treatment of cancer. The approach of discovering activators of enzymes has the potential to be a unique and broadly applicable technology platform for developing therapies to multiple oncology indications.

Calithera Biosciences Headquarter Location

343 Oyster Point Blvd Suite 200

South San Francisco, California, 94080,

United States

650-870-1000

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Calithera Biosciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Calithera Biosciences is included in 2 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Calithera Biosciences Patents

Calithera Biosciences has filed 44 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Experimental cancer drugs
  • Monoclonal antibodies
patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/8/2017

4/5/2022

Clusters of differentiation, Immunology, Immune system, Monoclonal antibodies, Transcription factors

Grant

Application Date

11/8/2017

Grant Date

4/5/2022

Title

Related Topics

Clusters of differentiation, Immunology, Immune system, Monoclonal antibodies, Transcription factors

Status

Grant

Latest Calithera Biosciences News

Calithera Biosciences stock slips after PT cut at Ladenburg

May 11, 2022

Calithera Biosciences (NASDAQ: CALA ) stock plunges after Ladenburg analyst Aydin Huseynov lowered the price target to $1.50 from $3 and maintains a Buy rating on the shares after its Q1 results . The company is developing two recently in-licensed oncology assets simultaneously, but the current cash burn and the stock performance do not support this approach, Huseynov tells investors in a research note. The analyst believes Calithera ( CALA ) needs to focus only on mivavotinib and slash its expenses in order to be able to make it to the next inflection point early next year. Cash and cash equivalents of $44.7M together with proceeds from its public offering is expected to be sufficient to fund its operating plan through 2Q23. “We made significant headway in the transfer of mivavotinib and sapanisertib materials to Calithera during the first quarter and are well into site start-up activities. We are on track to begin enrolling patients in both mivavotinib and sapanisertib trials in the second quarter of 2022 and expect to share data from these studies by the first quarter of 2023,” said Susan Molineaux, PhD, president and chief executive officer of Calithera. “We are also excited about our preclinical synthetic lethality program, having presented the first data from our internally-discovered, first-of-their-kind VPS4A inhibitors at the AACR Annual Meeting. This year has shaped up to be an exciting one for Calithera, given the potential we see in both our clinical and preclinical programs.” To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser. If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.

Calithera Biosciences Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Calithera Biosciences Rank

  • Where is Calithera Biosciences's headquarters?

    Calithera Biosciences's headquarters is located at 343 Oyster Point Blvd, South San Francisco.

  • What is Calithera Biosciences's latest funding round?

    Calithera Biosciences's latest funding round is IPO.

  • How much did Calithera Biosciences raise?

    Calithera Biosciences raised a total of $101.24M.

  • Who are the investors of Calithera Biosciences?

    Investors of Calithera Biosciences include Morgenthaler Ventures, Advanced Technology Ventures, Delphi Ventures, T. Rowe Price, Longwood Fund and 5 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.